ERBB2 and neoplasm: In consideration of HER2 expression heterogeneity between primary gastric/GEJ tumors and metastases as well as intratumoral HER2 expression heterogeneity, the application of anti-HER2 targeted therapy is markedly influenced by the analyzed tumor tissue/area.